We developed an experimental tumour metastasis model that allowed differential exposure of the primary and metastatic tumour site to the angiogenic agent basic fibroblast growth factor (bFGF), in order to vary primary tumour vascularity without altering tumour genotype. This evidence concerns the gene FGF2 and neoplasm.